에서 실시간으로 운영 중이에요! 자세히 알아보기
AMPH 아이콘

Amphastar Pharmaceuticals

25.87 USD
-0.55
2.08%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
25.80
-0.07
0.27%
1일
-2.08%
5일
-2.82%
1개월
8.02%
3개월
30.26%
6개월
18.62%
연초 이후
-2.23%
1년
11.41%
5년
35.94%
10년
43.4%
 

소개: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

직원 수: 1,976

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 33.3%
중립 41.7%
부정적 25%
긍정적
Zacks Investment Research
10일 전
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
중립
PRNewsWire
지난달
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
긍정적
Zacks Investment Research
지난달
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
부정적
Zacks Investment Research
2개월 전
New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
New Strong Sell Stocks for August 14th
중립
Seeking Alpha
2개월 전
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
긍정적
Zacks Investment Research
2개월 전
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
긍정적
Zacks Investment Research
2개월 전
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
부정적
MarketBeat
2개월 전
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
중립
PRNewsWire
2개월 전
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
부정적
Zacks Investment Research
2개월 전
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Lightweight Charts™를 사용해 가격 차트를 구현했어요.